Do Postpartum Levels of Apolipoproteins Prospectively Predict the Development of Type 2 Diabetes in Women with Previous Gestational Diabetes Mellitus?

Abstract

Aims The risk of developing type 2 diabetes is greater in women with previous gestational diabetes mellitus (GDM). Apolipoprotein (Apo) species have been associated with the development of type 2 diabetes in the general population. The aim of this study was to determine if circulating levels of Apo species can predict development of type 2 diabetes in women with previous GDM.

Methods Apo AI, Apo AII, Apo B, Apo CII, Apo CIII and Apo E levels were measured in 95 women with normal glucose tolerance, 12 weeks following an index GDM pregnancy. Women were assessed for up to 10 years for the development of type 2 diabetes.

Results Postpartum Apo CIII levels, and Apo CIII/Apo AI, Apo CIII/Apo AII, Apo CIII/Apo CII, Apo CIII/Apo E and Apo E/Apo CIII ratios were significantly and positively associated with the development of type 2 diabetes. After controlling for age and BMI, these associations, except for the Apo E/Apo CIII ratio, remained significant. In a clinical model of prediction of type 2 diabetes that included age, BMI, and pregnancy and postnatal fasting glucose, the addition of Apo CIII levels, Apo CIII/Apo AI, Apo CIII/Apo AII, Apo CIII/Apo CII, and Apo CIII/Apo E resulted in a net reclassification improvement of 16.2%.

Conclusions High Apo CIII levels and the Apo CIII/Apo AI, Apo CIII/Apo AII, Apo CIII/Apo CII, and Apo CIII/Apo E ratios are all significant risk factors for the development of type 2 diabetes in women with a previous GDM pregnancy.

Key words

gestational diabetes mellitus - apolipoproteins - type 2 diabetes

• References

• 1 Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus–present and future perspectives. Nature reviews Endocrinology 2012; 8: 228-236
• 2 Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes research and clinical practice 2010; 87: 4-14
• 3 Lee AJ, Hiscock RJ, Wein P. et al. Gestational diabetes mellitus: Clinical predictors and long-term risk of developing type 2 diabetes: A retrospective cohort study using survival analysis. Diabetes Care 2007; 30: 878-883
• 4 Ratner RE, Christophi CA, Metzger BE. et al. Prevention of diabetes in women with a history of gestational diabetes: Effects of metformin and lifestyle interventions. The Journal of clinical endocrinology and metabolism 2008; 93: 4774-4779
• 5 Lappas M, Jinks D, Ugoni A. et al. Post-partum plasma C-peptide and ghrelin concentrations are predictive of type 2 diabetes in women with previous gestational diabetes mellitus. Journal of diabetes 2015; 7: 506-511
• 6 Damm P, Kuhl C, Hornnes P. et al. A longitudinal study of plasma insulin and glucagon in women with previous gestational diabetes. Diabetes care 1995; 18: 654-665
• 7 Lappas M, Jinks D, Shub A. et al. Postpartum IGF-I and IGFBP-2 levels are prospectively associated with the development of type 2 diabetes in women with previous gestational diabetes mellitus. Diabetes & metabolism 2016; 42: 442-447
• 8 Lappas M, Mundra PA, Wong G. et al. The prediction of type 2 diabetes in women with previous gestational diabetes mellitus using lipidomics. Diabetologia 2015; 58: 1436-1442
• 9 Wu X, Yu Z, Su W. et al. Low levels of ApoA1 improve risk prediction of type 2 diabetes mellitus. Journal of Clinical Lipidology 2017; 11: 362-368
• 10 Onat A, Hergenç G, Bulur S. et al. The paradox of high apolipoprotein A-I levels independently predicting incident type-2 diabetes among Turks. International Journal of Cardiology 2010; 142: 72-79
• 11 Ley SH, Harris SB, Connelly PW. et al. Association of apolipoprotein b with incident type 2 diabetes in an aboriginal canadian population. Clinical Chemistry 2010; 56: 666-670
• 12 Seo MH, Bae JC, Park SE. et al. Association of lipid and lipoprotein profiles with future development of type 2 diabetes in nondiabetic korean subjects: A 4-year retrospective, longitudinal study. The Journal of Clinical Endocrinology & Metabolism 2011; 96: E2050-E2054
• 13 Onat A, Can G, Hergenc G. et al. Serum apolipoprotein B predicts dyslipidemia, metabolic syndrome and, in women, hypertension and diabetes, independent of markers of central obesity and inflammation. Int J Obes 2007; 31: 1119-1125
• 14 Hwang YC, Ahn HY, Kim WJ. et al. Increased apoB/A-I ratio independently associated with Type 2 diabetes mellitus: Cross-sectional study in a Korean population. Diabetic Medicine 2012; 29: 1165-1170
• 15 Zheng S, Han T, Xu H. et al. Associations of apolipoprotein B/apolipoprotein A-I ratio with pre-diabetes and diabetes risks: A cross-sectional study in Chinese adults. BMJ Open 2017; 7
• 16 Brahimaj A, Ligthart S, Ikram MA. et al. Serum levels of apolipoproteins and incident type 2 diabetes: A prospective cohort study. Diabetes Care 2017; 40: 346-351
• 17 Genuth S, Alberti KG, Bennett P. et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes care 2003; 26: 3160-3167
• 18 Onat A, Hergenc G, Ayhan E. et al. Serum apolipoprotein C-III in high-density lipoprotein: A key diabetogenic risk factor in Turks. Diabetic Medicine: A journal of the British Diabetic Association 2009; 26: 981-988
• 19 Taskinen MR, Boren J. Why is apolipoprotein ciii emerging as a novel therapeutic target to reduce the burden of cardiovascular disease?. Current Atherosclerosis Reports 2016; 18: 59
• 20 Maeda N, Li H, Lee D. et al. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. The Journal of Biological Chemistry 1994; 269: 23610-23616
• 21 Ito Y, Azrolan N, O'Connell A. et al. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science (New York, NY) 1990; 249: 790-793
• 22 Brown WV, Baginsky ML. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochemical and Biophysical Research Communications 1972; 46: 375-382
• 23 Windler E, Havel RJ. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. Journal of Lipid Research 1985; 26: 556-565
• 24 Sundaram M, Zhong S, Bou Khalil M. et al. Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. Journal of Lipid Research 2010; 51: 150-161
• 25 Kawakami A, Aikawa M, Alcaide P. et al. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation 2006; 114: 681-687
• 26 Qamar A, Khetarpal SA, Khera AV. et al. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. Arteriosclerosis, Thrombosis, and Vascular Biology 2015; 35: 1880-1888
• 27 Sacks FM, Alaupovic P, Moye LA. et al. VLDL, Apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation 2000; 102: 1886-1892
• 28 Carpenter MW. Gestational diabetes, pregnancy hypertension, and late vascular disease. Diabetes care 2007; 30 (Suppl. 02) S246-S250
• 29 Dallinga-Thie GM, Berk-Planken IIL, Bootsma AH. et al. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and hdl in type 2 diabetes. A Potential Mechanism to Lower Plasma Triglycerides 2004; 27: 1358-1364
• 30 Hertz R, Bishara-Shieban J, Bar-Tana J. Mode of action of peroxisome proliferators as hypolipidemic drugs: Suppression of apolipoprotein C-III. Journal of Biological Chemistry 1995; 270: 13470-13475